Searching for smart, safe news you can TRUST?
Support safe, smart, REAL journalism. Sign up for our Axios AM & PM newsletters and get smarter, faster.
Searching for smart, safe news you can TRUST?
Support safe, smart, REAL journalism. Sign up for our Axios AM & PM newsletters and get smarter, faster.
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Minneapolis-St. Paul
Tampa-St. Petersburg news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa-St. Petersburg
Photo: Dominick Reuter/AFP/Getty Images
A promising new drug called BAN2401 generated a lot of excitement after a clinical trial found it slowed the progression of Alzheimer’s by 30%, but recent revelations have left investors and doctors with more questions than answers, reports Bloomberg.
The bottom line: Whenever you hear about a promising new Alzheimer’s treatment, make a mental note to check back in a few months — or even a few days — to see if it’s still worth your attention.
The details: High doses of the drug, which is being developed by Biogen Inc. and Eisai Co., seemed to get results, but lower doses didn’t show any benefit. It turned out that people with a gene mutation that’s associated with Alzheimer’s were kept out of the high-dose group, at the request of regulators. That made it harder to tell whether the results for the high-dose group actually meant anything.
Go deeper: Alzheimer's research yields some promising results.